Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments

• Record Nr.: UNINA9910557489703321
• Autore: Uchino Junji
• Pubbl/distr/stampa: Basel, Switzerland, : MDPI - Multidisciplinary Digital Publishing Institute, 2021
• Descrizione fisica: 1 electronic resource (258 p.)
• Soggetti: Medicine
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Sommario/riassunto: Conventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed. Cancer cases that were highly responsive to gefitinib were later discovered to have epithelial growth factor receptor (EGFR) mutations. This discovery opened the door for biomarker-based treatment strategies. Subsequently, several EGFR-tyrosine kinase inhibitors (TKI) were developed, and they became a new mainstay of treatment for non-small cell lung cancer. In recent years, many mechanisms of resistance to EGFR-TKI have been elucidated; a mutation in the T790M gene at exon 20 is found in half of the resistant cases. Hence, osimertinib, which specifically inhibits EGFR despite this T790M gene mutation, was developed to achieve long-term progression-free survival. Other driver mutations that are similar to the EGFR mutation were discovered, including the EML4-ALK fusion gene (discovered in 2007), ROS1 gene, and BRAF gene mutations. The TKIs for each of these fusion genes were developed and are used as therapeutic agents. Another advancement in advanced non-small cell lung cancer is the development of immune checkpoint inhibitors. Four PD-1/PD-L1 inhibitors, including nivolumab, are currently available for treatment of lung cancer. These drugs prevent an escape from the cancer immunity cycle. This ensures that cancer cells will express cancer antigens, causing an anticancer immune response. Due to ; cancer immunotherapy, long-term survival is possible. The biomarker development for cancer immunotherapy and its side effects are actively being studied.

Ad-Hoc, Mobile, and Wireless Networks : 18th International Conference on Ad-Hoc Networks and Wireless, ADHOC-NOW 2019, Luxembourg, Luxembourg, October 1–3, 2019, Proceedings / / edited by Maria Rita Palattella, Stefano Scanzio, Sinem Coleri Ergen

• Record Nr.: UNINA9910349278103321
• Pubbl/distr/stampa: Cham : , : Springer International Publishing : , : Imprint : Springer, , 2019
• ISBN: 3-030-31831-1
• Edizione: [1st ed. 2019.]
• Descrizione fisica: 1 online resource (XV, 645 p. 262 illus., 188 illus. in color.)
• Collana: Computer Communication Networks and Telecommunications ; ; 11803
• Disciplina: 004.685
• Soggetti: Computer communication systems; Special purpose computers; Computer system failures; Application software; Coding theory; Information theory; Data encryption (Computer science); Computer Communication Networks; Special Purpose and Application-Based Systems; System Performance and Evaluation; Information Systems Applications (incl. Internet); Coding and Information Theory; Cryptology
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: Includes index.
• Sommario/riassunto: This book constitutes the refereed proceedings of the 18th ; International Conference on Ad-Hoc, Mobile, and Wireless Networks, ADHOC-NOW 2019, held in Luxembourg, in October 2019. The 37 full and 10 short papers presented were carefully reviewed and selected from 64 submissions. The papers provide an in-depth and stimulating view on the new frontiers in the field of mobile, ad hoc and wireless computing. They are organized in the following topical sections: IoT for emergency and disaster management; scheduling and synchronization in WSN; routing strategies for WSN; LPWANs and their integration with satellite; performance improvement of wireless and sensor networks; optimization schemes for increasing sensors lifetime; vehicular and UAV networks; body area networks, IoT security and standardization.